Trial Profile

Alogliptin versus voglibose in NAFLD patients with impaired glucose tolerance or type 2 diabetes mellitus.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Jul 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alogliptin (Primary) ; Voglibose
Indications Glucose intolerance; Type 2 diabetes mellitus
Focus Pharmacodynamics

Most Recent Events

01 Jul 2011 New trial record
28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com